Clearmind Medicine Inc.

NasdaqCM CMND

Clearmind Medicine Inc. Price to Book Ratio (P/B) on December 30, 2024

Clearmind Medicine Inc. Price to Book Ratio (P/B) is NA on December 30, 2024, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Clearmind Medicine Inc. 52-week high Price to Book Ratio (P/B) is 2.71 on February 23, 2024, which is NA below the current Price to Book Ratio (P/B).
Clearmind Medicine Inc. 52-week low Price to Book Ratio (P/B) is 1.56 on April 02, 2024, which is NA below the current Price to Book Ratio (P/B).
Clearmind Medicine Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 1.97.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqCM: CMND

Clearmind Medicine Inc.

CEO	Dr. Adi Zuloff-Shani Ph.D.
IPO Date	Nov. 15, 2022
Location	Canada
Headquarters	1220 West 6th Avenue
Employees	4
Sector	Health Care
Industries Pharmaceuticals Mental Health

Description

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Key trends

Past 5 years